RFL - Rafael gets enrollment underway in Phase 1/2 CPI-613 clear cell sarcoma study

Rafael Pharmaceuticals (NYSE:RFL) announces that the first patient has been enrolled in the APOLLO 613 Phase 1/2 trial of CPI-613 (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma. Two additional sites have also been opened for enrollment in the trial at Cleveland Clinic Children’s and University of Michigan’s Rogel Cancer Center. CPI-613 is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Clear cell sarcoma is very difficult to diagnose, and the average age of diagnosis is 25 years old. By the time the disease is diagnosed, it is often in advanced stages when the cancer is aggressive and hard to treat.

For further details see:

Rafael gets enrollment underway in Phase 1/2 CPI-613 clear cell sarcoma study